Biosergen PER forward

Que fait Biosergen ? Biosergen AB is a biopharmaceutical company headquartered in Solna, Sweden. The company went public on June 24, 2021, with its ticker symbol BIOSGN.ST and ISIN SE0026821852. Biosergen AB conducts biopharmaceutical research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The company is focused on developing BSG005, an antifungal drug that has shown safety and potency benefits compared to existing treatments. BSG005 is designed to address invasive fungal infections affecting immune-compromised patients, including those with AIDS, cancer, or who have undergone transplants. At equivalent doses, BSG005 has demonstrated a three- to fourfold higher potency against targeted fungal strains than current standard treatments, while avoiding the kidney toxicity associated with other drugs in its class. Biosergen AB operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is biosergen.net, providing further information about its research and development activities. The firm's primary focus remains on advancing BSG005 through clinical development, targeting a significant unmet medical need in the treatment of fungal infections among vulnerable patient populations. Biosergen est l'une des entreprises les plus populaires sur Eulerpool.